Ritually Ill Covid-19 Across UK Gets Access To New Drugs That Can “Substantially” Reduce Risk Of Death From The US Virus

NHS patients admitted to the country’s intensive care units can receive tocilizumab and sarilumab It has also been found to reduce the time coronavirus patients spend in hospital by up to 10 days

The drugs normally used to treat rheumatoid arthritis will be included in updated guidelines to be released tomorrow by the government and the NHS to trusts across the UK

Results from the government-funded REMAP-CAP clinical trial showed that both drugs reduced mortality risk by 8.5 percent when administered to patients within one day of ICU entry alongside a corticosteroid such as dexamethasone

Professor Anthony Gordon, Chair of Anaesthesiology and Critical Care Medicine at Imperial College London and Critical Care Consultant at Imperial College Healthcare NHS Trust, said, “This is a significant finding that could have an immediate impact on the sickest patients with Covid -19.” / p>

“We have found that in critically ill adult patients – who receive respiratory support in the intensive care unit – treatment with these drugs can improve their chances of survival and recovery

“At a time when hospital stays and deaths from Covid-19 are on the rise in the UK, it is critical that we continue to identify effective treatments that can help turn the tide on this disease””

The results, presented to a peer-reviewed journal, are based on an analysis of 803 patients from six countries, of whom 353 were assigned tocilizumab and 48 sarilumab

The hospital mortality rate was 273 percent in patients who received tocilizumab or sarilumab, compared with 358 percent of patients in the control group who did not receive the medication, the researchers said

It is believed that tocilizumab or sarilumab treatment between 750 and 1Costs £ 000 and is given as either one or two intravenous doses

Professor Gordon added, “For every 12 ICU patients you treat with these drugs, based on the evidence available, you would save a life”

Health Secretary Matt Hancock said: “The UK has proven time and again that it is at the forefront of identifying and delivering the most promising and innovative treatments to its patients

“Today’s results are another milestone in the search for a way out of this pandemic When added to the vaccines and treatments already in place, they will play an important role in fighting this virus

“We worked quickly to ensure that this treatment was immediately available to NHS patients, which means hundreds of lives will be saved”

Deputy Chief Physician Professor Jonathan Van-Tam said: “This is a significant step forward to improve the survival of patients in the intensive care unit with Covid-19

“The data shows that tocilizumab and probably sarilumab accelerate and improve the chances of recovery in the intensive care unit This is critical to easing the pressure on the ICU and hospitals and saving lives ”

Tocilizumab and sarilumab have been added to the government’s export restriction list, the Department of Health and Social Welfare (DHSC) said

This will protect UK patient care by enforcing regulatory action against those who break the restrictions, he added

Peter Horby, Professor of Emerging Infectious Diseases at the Center for Tropical Medicine and Global Health at Oxford University, commented on the results: “It’s great to see a positive outcome at a time when we really need and need good news more tools to fight Covid

“This is a great achievement for REMAP-CAP – it shows the power of adaptive platform testing

“It is important that the results of a benefit are in addition to the corticosteroids, which were used by 93 percent of the participants

Tocilizumab

World News – GB – UK Covid Patients Received New Drugs That Reduce Risk of Death by 24%

Source: https://www.standard.co.uk/news/uk/tocilizumab-sarilumab-covid-drugs-treatment-b743038.html